Information about Filspari (Sparsentan)
Filspari (Sparsentan) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of kidney disease, particularly focal segmental glomerulosclerosis (FSGS) and IgA nephropathy. It is a dual-targeted therapy, designed to selectively block two pathways—endothelin A (ETA) receptors and angiotensin II type 1 (AT1) receptors—to help slow the progression of kidney damage in these conditions.
Primary Indications for Filspari (Sparsentan)
- FSGS is a condition that leads to kidney scarring and can result in end-stage renal disease (ESRD). Sparsentan is indicated for the treatment of FSGS in adults who have high levels of protein in their urine.
- A kidney disease caused by the deposition of immunoglobulin A (IgA) in the kidneys, leading to inflammation and scarring. Sparsentan is indicated for the treatment of IgAN to reduce proteinuria and slow disease progression.
Key Ingredient
Key Benefits
- One of the primary benefits of Filspari is its ability to significantly reduce proteinuria, a major marker of kidney damage.
- By addressing two key pathways that contribute to kidney damage, Sparsentan helps slow the progression of kidney disease in conditions like FSGS and IgA nephropathy.
- Through reduction of protein in the urine and lowering kidney inflammation, it may help maintain or improve renal function.
- The combination of blocking endothelin A receptors and angiotensin II receptors offers a broader approach to kidney protection compared to medications that target only one pathway.
Direction of Use
- Filspari (Sparsentan) is typically taken once daily as an oral tablet.
- The recommended starting dose is generally 200 mg per day, which may be adjusted based on the patient's response and tolerance.
- It should be taken with or without food.
- Regular monitoring of kidney function (e.g., serum creatinine levels) and blood pressure is required during treatment.
Safety Concerns
- Sparsentan can lower blood pressure, so patients should be monitored regularly for hypotension, especially when starting the medication or increasing the dose.
- As Sparsentan affects kidney function, kidney parameters (creatinine levels, eGFR) should be monitored closely.
- There may be fluid retention in some patients, particularly those with worsening kidney function.
- Since Sparsentan affects the renin-angiotensin-aldosterone system, it could lead to elevated potassium levels, which need to be monitored.
- Sparsentan is contraindicated during pregnancy due to potential harm to the fetus (teratogenic effects). It should be avoided in pregnant women.
Avoid Filspari (Sparsentan) If
- It is contraindicated during pregnancy because it can cause fetal harm.
- In patients with severe renal impairment (e.g., eGFR < 30 mL/min/1.73 m²), Sparsentan should not be used, as its safety and efficacy have not been established in these patients.
- If a patient has a known allergy to Sparsentan or any component of the medication, it should be avoided.
- Sparsentan should be avoided in patients with severe liver impairment (Child-Pugh Class C) as it may increase the risk of side effects.
- Sparsentan should be used cautiously or avoided in individuals with uncontrolled hyperkalemia or severely low blood pressure.
